Insider Selling: Dyne Therapeutics, Inc. (NASDAQ:DYN) Insider Sells $61,342.05 in Stock

Dyne Therapeutics, Inc. (NASDAQ:DYNGet Free Report) insider Oxana Beskrovnaya sold 2,373 shares of Dyne Therapeutics stock in a transaction dated Thursday, March 7th. The shares were sold at an average price of $25.85, for a total value of $61,342.05. Following the transaction, the insider now directly owns 154,433 shares in the company, valued at $3,992,093.05. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Oxana Beskrovnaya also recently made the following trade(s):

  • On Wednesday, January 3rd, Oxana Beskrovnaya sold 45,326 shares of Dyne Therapeutics stock. The stock was sold at an average price of $18.98, for a total transaction of $860,287.48.

Dyne Therapeutics Stock Performance

NASDAQ DYN traded up $0.39 during trading on Monday, hitting $25.55. The stock had a trading volume of 1,257,496 shares, compared to its average volume of 2,442,931. Dyne Therapeutics, Inc. has a one year low of $6.40 and a one year high of $30.27. The stock has a 50 day simple moving average of $21.22 and a 200 day simple moving average of $13.95. The stock has a market capitalization of $1.57 billion, a price-to-earnings ratio of -6.48 and a beta of 0.95.

Dyne Therapeutics (NASDAQ:DYNGet Free Report) last posted its quarterly earnings results on Tuesday, March 5th. The company reported ($1.09) EPS for the quarter, missing the consensus estimate of ($0.92) by ($0.17). On average, sell-side analysts predict that Dyne Therapeutics, Inc. will post -3.09 EPS for the current year.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the stock. HC Wainwright reissued a “buy” rating and issued a $36.00 price objective on shares of Dyne Therapeutics in a research note on Wednesday, March 6th. Piper Sandler lifted their target price on Dyne Therapeutics from $27.00 to $29.00 and gave the company an “overweight” rating in a research note on Wednesday, March 6th. Oppenheimer reissued an “outperform” rating and issued a $47.00 price target (up from $44.00) on shares of Dyne Therapeutics in a report on Tuesday, March 5th. StockNews.com raised shares of Dyne Therapeutics to a “sell” rating in a report on Thursday, December 21st. Finally, Stifel Nicolaus upped their target price on shares of Dyne Therapeutics from $35.00 to $41.00 and gave the stock a “buy” rating in a research report on Wednesday, March 6th. One equities research analyst has rated the stock with a sell rating, six have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $37.43.

Read Our Latest Stock Report on Dyne Therapeutics

Institutional Trading of Dyne Therapeutics

Large investors have recently modified their holdings of the company. Assenagon Asset Management S.A. raised its holdings in shares of Dyne Therapeutics by 24.5% in the 3rd quarter. Assenagon Asset Management S.A. now owns 721,474 shares of the company’s stock valued at $6,464,000 after purchasing an additional 142,083 shares in the last quarter. Acuta Capital Partners LLC lifted its holdings in Dyne Therapeutics by 100.7% during the third quarter. Acuta Capital Partners LLC now owns 146,500 shares of the company’s stock worth $1,313,000 after buying an additional 73,500 shares during the period. TD Asset Management Inc bought a new stake in Dyne Therapeutics during the 3rd quarter valued at $206,000. Profund Advisors LLC increased its holdings in shares of Dyne Therapeutics by 9.8% in the 3rd quarter. Profund Advisors LLC now owns 23,793 shares of the company’s stock valued at $213,000 after acquiring an additional 2,131 shares during the period. Finally, Franklin Resources Inc. raised its position in shares of Dyne Therapeutics by 1.1% in the 2nd quarter. Franklin Resources Inc. now owns 1,913,479 shares of the company’s stock worth $21,527,000 after acquiring an additional 21,120 shares in the last quarter. Hedge funds and other institutional investors own 96.68% of the company’s stock.

About Dyne Therapeutics

(Get Free Report)

Dyne Therapeutics, Inc, a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.

Recommended Stories

Insider Buying and Selling by Quarter for Dyne Therapeutics (NASDAQ:DYN)

Receive News & Ratings for Dyne Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dyne Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.